Browsing Tag
European Medicines Agency
66 posts
Why the EMA review of PolTREG-T1D could influence autoimmune cell therapy development
PolTREG-T1D moves toward European Medicines Agency review. Discover how this TREG cell therapy could reshape treatment for autoimmune diseases.
United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
United Therapeutics reports strong Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis. Discover why this inhaled therapy could reshape treatment.
How FIREFLY1 data positioned Ojemda for conditional EU approval in pediatric glioma
How FIREFLY1 data positioned Ipsen’s Ojemda for conditional EU approval in pediatric glioma and what it means for investors and competitors.
Will mavorixafor’s EU path mirror its U.S. regulatory breakthrough in WHIM syndrome?
X4 Pharmaceuticals (NASDAQ: XFOR) wins EMA backing for mavorixafor. Explore what EU approval could mean for revenue, risk, and rare disease strategy.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
Savara Inc. (NASDAQ: SVRA) moves closer to first approval as FDA files MOLBREEVI BLA with priority review
Savara Inc. has secured FDA priority review for MOLBREEVI in autoimmune PAP. Find out what this means for approval odds, investors, and rare lung care.
EC backs higher-dose Wegovy as obesity competition intensifies
Novo Nordisk A/S wins EU approval for 7.2 mg Wegovy. Discover how this shifts obesity competition, reimbursement, and long-term strategy.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Sanofi’s second chance: Why Europe is warming up to Rezurock after initial CHMP rejection
Sanofi’s Rezurock secures EU conditional approval recommendation for chronic GVHD. Find out what changed and how this could reshape rare disease care.